6CM
TERN

683 Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

683 Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,000
Closed -$189K – 245
2023
Q1 		$189K Sell
16,000
-12,000
-43% -$115K 0.01% 163
2022
Q4 		$285K Buy
+28,000
New +$186K 0.02% 133

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

683 Capital Management's TERN Position: Q2 2023 in Review

683 Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2023, closing a stake of 16,000 shares — an estimated $189K sold.

683 Capital Management first reported a position in TERN in Q4 2022 and held it in 2 quarters. The position peaked at $285K in Q4 2022. 103 funds tracked by Wall St. Rank hold TERN as of Q2 2023.

  • 683 Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 16,000 Terns Pharmaceuticals shares in Q2 2023, an estimated $189K.
  • 683 Capital Management first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Terns Pharmaceuticals position peaked at $285K in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.